These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 32032244)
1. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. Hillier K; Cheng WS; Whittle SB; Krance R; Foster JH J Pediatr Hematol Oncol; 2020 Oct; 42(7):e569-e574. PubMed ID: 32032244 [TBL] [Abstract][Full Text] [Related]
2. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174 [TBL] [Abstract][Full Text] [Related]
3. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers. Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402 [TBL] [Abstract][Full Text] [Related]
4. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340 [TBL] [Abstract][Full Text] [Related]
5. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923 [TBL] [Abstract][Full Text] [Related]
6. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Soni S; Pai V; Gross TG; Ranalli M Pediatr Transplant; 2014 Mar; 18(2):217-20. PubMed ID: 24341617 [TBL] [Abstract][Full Text] [Related]
7. Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources. Elzembely MM; Park JR; Riad KF; Sayed HA; Pinto N; Carpenter PA; Baker KS; El-Haddad A J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30241255 [TBL] [Abstract][Full Text] [Related]
8. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413 [TBL] [Abstract][Full Text] [Related]
10. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062 [TBL] [Abstract][Full Text] [Related]
11. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045 [TBL] [Abstract][Full Text] [Related]
12. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens. Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778 [TBL] [Abstract][Full Text] [Related]
13. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113 [TBL] [Abstract][Full Text] [Related]
14. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658 [TBL] [Abstract][Full Text] [Related]
15. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y; Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211 [TBL] [Abstract][Full Text] [Related]
16. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. Sakaguchi H; Muramatsu H; Hasegawa D; Kudo K; Ishida H; Yoshida N; Koh K; Noguchi M; Shiba N; Tokimasa S; Fukuda T; Goto H; Miyamura T; Nakazawa Y; Hashii Y; Inoue M; Atsuta Y; Pediatr Blood Cancer; 2019 Jan; 66(1):e27459. PubMed ID: 30270523 [TBL] [Abstract][Full Text] [Related]
17. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365 [TBL] [Abstract][Full Text] [Related]
18. Analysis of pediatric autologous PBSC apheresis and transplant: age is a major factor affecting post-transplant toxicity. Dubrovsky L; McCarter RJ; Fry TJ; Wong E; Cheng Y; Perez-Albuerne ED Pediatr Blood Cancer; 2012 Aug; 59(2):301-5. PubMed ID: 22180259 [TBL] [Abstract][Full Text] [Related]